Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose cytarabine plus arsenic trioxide for elderly non-promyelocytic acute myeloid leukemia
IRCT138711061030N5Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cytarabine and arsenic trioxide in acute myeloid leukemia (AML), sponsored by Tehran University of Medical Sciences. Started Oct 2007; status: completed.
02
Drugs
cytarabinearsenic trioxide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT138711061030N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT138711061030N5.